Immunologix Teams with GenScript to Produce Human Antibody Therapeutics Ready for Clinical Trials

CHARLESTON, S.C. & PISCATAWAY, N.J.--(EON: Enhanced Online News)--Immunologix, Inc, a Charleston, SC biotechnology company and a leader in fully human therapeutic antibodies for a variety of diseases and GenScript, a contract research organization (CRO) based in Piscataway, NJ and the industry leader in bio-reagent services, assay development & screening, lead optimization, and antibody drug development, announced today that the companies have formed a strategic partnership to offer a complete platform for producing human antibody therapeutics. Immunologix holds the exclusive worldwide license rights to a proprietary technique used to produce fully human antibodies. GenScript offers extensive antibody drug services that include antigen production, hybridoma development and stabilization, antibody sequencing, chimeric antibody, antibody humanization, affinity maturation, epitope mapping, antibody and protein characterization, in vitro assay and screening, in vivo efficacy and safety study, antibody transient expression, stable cell line, and scale up production. Jointly, the companies provide an integrated platform for discovery and development of full human therapeutic antibody candidates ready for clinical trials.